I want peptides.

What Is Melanotan II (MT-2)?

Our best pick for research peptides is Oath Research, whose policy offers refunds or replacements for product that misses stated specifications or purity; opened or used product is excluded.

Melanotan II (MT-2) is a synthetic cyclic seven-amino-acid analogue of alpha-melanocyte-stimulating hormone (α-MSH) synthesized at the University of Arizona in the late 1980s. Because it acts as a non-selective agonist across four melanocortin receptor subtypes (MC1R, MC3R, MC4R, and MC5R), it simultaneously stimulates skin eumelanin synthesis, central sexual arousal, and appetite suppression—and carries documented dermatological and cardiovascular risks that prevented its approval as a human drug.

Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
Structure
Cyclic Lactam Heptapeptide (7-mer)
Receptor Profile
Non-Selective MC1R, MC3R, MC4R & MC5R
U.S. FDA Status
Unapproved; Cat. 2 Nomination Withdrawn

How Melanotan II Was Discovered (And Why It Differs From Melanotan I & PT-141)

In the 1980s, university researchers in Arizona sought to design stable synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH)—the natural 13-amino-acid pituitary peptide that signals epidermal melanocytes to synthesize dark eumelanin pigment (PubMed, PMID: 16503593). Because natural α-MSH has a plasma half-life of only a few minutes, investigators created two distinct structural analogues:

  • Melanotan I (Afamelanotide): A linear 13-amino-acid peptide ([Nle⁴, D-Phe⁷]-α-MSH) that selectively targets peripheral MC1R receptors on melanocytes. Afamelanotide eventually gained FDA approval (under the brand name Scenesse) as a subcutaneous implant for patients with the rare genetic disorder erythropoietic protoporphyria (EPP).
  • Melanotan II (MT-2): A shorter, cyclic lactam-bridged seven-amino-acid peptide (`Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂`). Melanotan II also affects central melanocortin pathways, with reported effects beyond pigmentation.
  • PT-141 (Bremelanotide): PT-141 is related to Melanotan II and is FDA-approved as Vyleesi for a specific indication.
An open unmarked envelope, blank note cards and a red pencil on a blue desk
Melanotan II and PT-141 differ by a single C-terminal functional group (amide -NH₂ in Melanotan II vs. hydroxyl -OH in PT-141), a structural distinction verified by analytical mass spectrometry (LC-MS).

The Four Melanocortin Receptors Activated by Melanotan II

Receptor Subtype Primary Tissue Location Downstream Physiological Effect
MC1R Cutaneous melanocytes (epidermis & hair follicles) Activates adenylyl cyclase → cAMP → MITF transcription → tyrosinase upregulation → synthesis of brown/black eumelanin pigment.
MC3R Hypothalamus, limbic system & macrophages Modulates energy partitioning, natriuresis, and autonomic signaling.
MC4R Hypothalamic paraventricular nucleus & brainstem Drives central sexual arousal pathways, suppresses appetite (anorexigenic signaling), and transiently elevates autonomic blood pressure and emetic (nausea) reflexes.
MC5R Exocrine & sebaceous glands Regulates sebaceous lipid secretion and thermoregulatory exocrine function.

Documented Safety Risks & Dermatological Warnings

Dermatology associations and regulatory agencies worldwide—including the U.S. Food and Drug Administration, Health Canada, the UK MHRA, and the Australian TGA—have issued formal public health warnings against the use of unapproved Melanotan II products for cosmetic tanning. Peer-reviewed dermatology and toxicology literature highlights five major areas of risk:

  1. Eruptive Melanocytic Nevi & Dysplastic Mole Changes: Because MC1R stimulation drives rapid melanocyte proliferation and pigment clumping, reported safety concerns include darkening and changes in moles (NIH PMC6933565).
  2. Autonomic & Cardiovascular Effects: Central MC4R activation causes acute facial flushing, gastrointestinal nausea/vomiting, and transient increases in systolic and diastolic blood pressure.
  3. Priapism & Renal Toxicity Reports: Health Canada warns that unauthorized tanning products may pose serious health risks. Toxicology reviewers note uncertainty about whether specific severe adverse events stem directly from high-dose melanocortin receptor overstimulation, from unlisted contaminants and synthesis impurities in unregulated grey-market vials, or from a combination of both. Anyone with existing kidney disease (renal impairment), hypertension, or cardiovascular disease faces heightened risk.
  4. Pregnancy & Breastfeeding Exclusion: Human fetal and neonatal safety is unestablished for Melanotan II.
  5. U.S. FDA Compounding Status (April 22, 2026): Melanotan II is not FDA-approved for any human indication, and its nomination for Section 503A bulk compounding was withdrawn on the FDA list current as of April 22, 2026.
Dermatological & Regulatory Warning

Melanotan II is an unapproved research chemical, not a safe or approved tanning product. Regulatory agencies warn that non-selective melanocortin stimulation can trigger rapid changes in melanocytic nevi (moles) and mask or complicate skin cancer surveillance.

How Melanotan II Compares to Safer Alternatives & Why Tanning Does Not Replace Sunscreen

Dermatologists emphasize two practical points for anyone researching cosmetic pigmentation or photoprotection:

  • Topical Dihydroxyacetone (DHA) Sunless Tanners: Cosmetic self-tanning lotions, foams, and spray tans use DHA, a simple carbohydrate that reacts non-enzymatically (via the Maillard reaction) with amino acids in the dead outermost layer of skin (the stratum corneum). DHA is used in topical cosmetic sunless tanners and acts differently from melanocortin peptides.
  • Natural Sun & Tanning Beds vs. Afamelanotide (Scenesse): Ultraviolet (UV) radiation from sunlight or indoor tanning beds causes direct pyrimidine dimer DNA damage in keratinocytes and melanocytes, accelerating photoaging and skin cancer risk. While prescription afamelanotide (Melanotan I / Scenesse) is FDA-approved strictly for patients with the rare genetic disorder erythropoietic protoporphyria (EPP) under specialized medical monitoring, it is not approved or indicated for cosmetic tanning.
  • The UV-Protection Caveat (Pigmentation Never Replaces Sunscreen): A common misconception is that darkening the skin with Melanotan II makes a person immune to sunburn or UV skin damage. Even dark eumelanin provides an endogenous Sun Protection Factor (SPF) equivalent to only about SPF 2 to 4—leaving epidermal DNA vulnerable to UVA and UVB radiation. Pigmentation induced by melanocortin analogs never replaces broad-spectrum sunscreen, protective clothing, or UV avoidance.

Scientific References and Further Reading

  1. α-Melanocyte-stimulating hormone analogs and their use in dermatology - PubMed
  2. U.S. Food and Drug Administration — Injectable Tanning Shots: Risky Business (Consumer Update)
  3. Health Canada — Health Product InfoWatch: Unauthorized Injectable Tanning Products (Melanotan)
  4. Melanotan: a confusing and deadly tan - National Institutes of Health
Educational Disclaimer: This article summarizes published pharmacology and dermatology literature for informational reference. We do not provide medical advice or human dosing instructions.